Publikasi Scopus 2024 per tanggal 30 April 2024 (334 artikel)

Simadibrata D.M.; Lesmana E.; Pratama M.I.A.; Sugiharta A.J.; Winarizal A.S.; Lee Y.Y.; Syam A.F.
Simadibrata, Daniel M (57202134322); Lesmana, Elvira (57208440285); Pratama, Muhammad I A (58202312500); Sugiharta, Adrianus J (57223013711); Winarizal, Afiah S (57217090886); Lee, Yeong Y (56191149300); Syam, Ari F (8443384400)
57202134322; 57208440285; 58202312500; 57223013711; 57217090886; 56191149300; 8443384400
A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis
2024
JGH Open
8
3
e13053
0
Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia; GI Function and Motility Unit, Hospital USM, Kota Bharu, Malaysia; Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia—Ciptomangkunkusumo General Hospital, Jakarta, Indonesia
Simadibrata D.M., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Lesmana E., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Pratama M.I.A., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Sugiharta A.J., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Winarizal A.S., Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia; Lee Y.Y., School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Malaysia, GI Function and Motility Unit, Hospital USM, Kota Bharu, Malaysia; Syam A.F., Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia—Ciptomangkunkusumo General Hospital, Jakarta, Indonesia
Introduction: Proton pump inhibitor (PPI) is the mainstay therapy for the maintenance of healed erosive esophagitis (EE). It is unknown whether potassium-competitive acid blockers (PCABs) are more efficacious and safer than PPIs. Methods: Only randomized controlled trials (RCTs) comparing PCABs to PPIs in the maintenance of healing rates of endoscopically proven healed EE and indexed in MEDLINE, EMBASE, and CENTRAL until 3 February 2024, were included. A fixed-effects model meta-analysis was performed to pool primary efficacy outcome (maintenance of healing rates at week 24) and safety data (any treatment-emergent adverse event or TEAE). The risk of bias was assessed using Cochrane's Risk of Bias 2 (RoB2) tool. Results: Four RCTs with a total of 2554 patients were eligible for inclusion. All trials were of low risk of bias. Compared to lansoprazole 15 mg, the maintenance rates of healed EE at week 24 were significantly higher with vonoprazan 10 mg (RR 1.13; 95% CI 1.07–1.19) and vonoprazan 20 mg (RR 1.15; 95% CI 1.10–1.21). Likewise, compared to lansoprazole 15 mg, any TEAEs were significantly greater with vonoprazan 20 mg (RR 1.10; 95% CI 1.01–1.20) but not vonoprazan 10 mg. Conclusion: Vonoprazan 10 and 20 mg were superior to lansoprazole 15 mg in the maintenance of the healing of EE. Any TEAEs were greater with vonoprazan 20 mg. © 2024 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
erosive esophagitis; maintenance; potassium-competitive acid blocker; proton pump inhibitor; vonoprazan
lansoprazole; potassium competitive acid blocker; proton pump inhibitor; tegoprazan; vonoprazan; adverse event; alcohol consumption; body mass; clinical outcome; comparative study; controlled study; data quality assessment; drug comparison; drug efficacy; drug safety; endoscopy; Helicobacter infection; human; intention to treat analysis; maintenance therapy; meta analysis; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; randomized controlled trial (topic); reflux esophagitis; Review; smoking; systematic review
John Wiley and Sons Inc
23979070
Review
Q3
522
9947